Sesen Bio Inc
Sesen Bio merged with Carisma Therapeutics in March 2023 and the combined entity operates as Carisma (CARM). Sesen's lead program Vicineum (VB4-845) for non-muscle invasive bladder cancer had its development paused in July 2022 after the FDA indicated additional Phase 3 work would be required.
Focus areas at Sesen Bio Inc
The clinical trials section below shows all active and recruiting studies sponsored by Sesen Bio Inc, sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites. The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Sesen Bio Inc is headquartered in San Francisco, United States, founded in 2010, a subsidiary of Carisma Therapeutics. The company maintains a dedicated rare disease division alongside its broader therapeutic portfolio, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Active Clinical Trials
FDA-Approved Drugs
Frequently Asked Questions About Sesen Bio Inc
Common questions about Sesen Bio Inc's rare disease programs, clinical trials, and treatments.